by Deb Wesloh & Lou Ann Donovan Apps can help Manage your Life with Cancer Mobile applications for smartphones and tablets, also known as apps, are becoming a rising resource to help people with cancer manage their day-to-day life. Apps are also an easy resource for family members to stay informed and provide support for […]
Differential cytokine network profile in Polycythemia Vera and Secondary Polycythemia
Authors: Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Maria Gabriela Berzoti-Coelho, Raquel Tognon, Natalia de Souza Nunes, Belinda Simões, Ítalo Sousa Pereira, Daniela Carlos, Lucia Helena Faccioli, Lorena Lobo de Figueiredo-Pontes, Fabiani Gai Frantz & Fabíola Attié de Castro Scientific Reports volume 10, Article number: 7032 (2020) Abstract Polycythemia vera (PV) is a clonal disorder resulting from neoplastic transformation of hematopoietic stem cells, while secondary polycythemia (SP) is a disease characterized by increased absolute […]
Immunotherapy in Myeloproliferative Diseases
by Lukas M. Braun 1,2 and Robert Zeiser 1,3,4,5,* 1 Department of Medicine I, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; lukas.braun@uniklinik-freiburg.de 2 Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany 3 German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 4 […]
PTG-300 Hepcidin Mimetic Receives FDA Orphan Drug Designation for Treatment of Polycythemia Vera
NEWARK, Calif., June 17, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis. “Receiving […]
MPN Hub Launches Open Access Resource
by David Wallace The MPN Hub is an “open-access” online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. The aim is to enhance knowledge in MPN, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. The MPN Hub shares new data, evidence-based articles, therapy approvals, […]
MPN Specialist Explains PTG-300 and Clinical Trial for PV Patients
by David Wallace Hepcidin Mimetic PTG-300 Promising Treatment for PV How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV? How does iron deficiency play a role in polycythemia vera? What are the goals of this treatment? Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David […]
Protagonist Therapeutics early Phase 2 results for Polycythemia Vera Treatment Encouraging
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
Phyllis George dies from Polycythemia Vera complications
The MPN Community needs a Celebrity Spokesperson to bring awareness of our “Rare Blood Disease” by David Wallace I’m saddened to hear that former Kentucky first lady and Miss America, Phyllis George passed away from a “rare blood disease” at 70. She was a true pioneer in the TV broadcast industry, as the first woman […]
Coping with COVID-19
Easy Ways to Stay Calm by Lou Ann Donovan How Are You Coping with the Coronavirus Pandemic? The COVID-19 pandemic has brought many changes in how we live our lives now. It has brought uncertainty, changes to daily routines, financial concerns and social isolation. You may be worrying about getting sick or what the future […]
The New WHO classification for Essential Thrombocythemia calls for revision of available evidences
Abstract In the 2016 revised classification of myeloproliferative neoplasms pre-fibrotic primary myelofibrosis (pre-PMF) was recognized as a separate entity, distinct from essential thrombocythemia (ET). Owing that the majority of cases falling in the pre-PMF category were previously diagnosed as ET, one may question about the need to re-evaluate the results of epidemiologic, clinical, and molecular […]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 20
- Next Page »
